In a report released yesterday, David Martin PhD from Bloom Burton maintained a Buy rating on AbCellera Biologics, with a price target of $9.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
David Martin PhD has given his Buy rating due to a combination of factors related to AbCellera Biologics’ strategic shift towards its internal pipeline. The company is focusing on two promising antibody therapeutics: ABCL635 and ABCL575. ABCL635 targets the neurokinin 3 receptor for treating vasomotor symptoms associated with menopause, while ABCL575 aims to block inflammatory signaling pathways by binding to the OX40 ligand on antigen-presenting cells. Both therapies address large potential markets with millions of affected individuals.
Despite the competitive landscape, even capturing a small market share could lead to substantial revenues for AbCellera. For instance, ABCL635 is projected to generate significant sales if it captures just a small percentage of the market for women with moderate to severe vasomotor symptoms. Although there is some uncertainty regarding the lead indication for ABCL575, the valuation is supported by precedent transactions and peer company comparisons. The overall valuation of AbCellera includes its partnered business and other financial considerations, maintaining a $9.00 target price and a speculative risk rating. This reflects the higher risk/reward potential of the company’s focus on proprietary drug development.